SWX:NOVNPharmaceuticals
Assessing Novartis (SWX:NOVN) Valuation After 2025 Results Dividend Proposal And 2026 Outlook
Novartis (SWX:NOVN) is back in focus after releasing its fourth quarter and full year 2025 results, pairing high single digit sales growth and a proposed higher dividend with softer guidance for 2026 core operating income.
See our latest analysis for Novartis.
The recent earnings release, softer 2026 core income guidance and the proposed CHF3.70 dividend appear to be contributing to building momentum. The 30 day share price return of 9.4% and 1 year total shareholder return of 24.7% extend...